Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

CRISPR Therapeutics applies to conduct clinical trial of CTX-001

Dec. 12, 2017

Janssen submits sNDA in U.S. for two new Xarelto indications

Dec. 12, 2017

OG-L002 shows promising in vivo results for the treatment of sickle cell disease

Dec. 11, 2017

Ra Pharmaceuticals reports interim results from phase II study of RA-101495 in PNH

Dec. 5, 2017

Novel hemorrhagic shock model reveals time window for intervention

Dec. 4, 2017

Daiichi Sankyo and Translational Sciences terminate TS-23 agreement

Dec. 4, 2017

Afstyla launched in Japan for the treatment of hemophilia A

Dec. 1, 2017

PhaseBio Pharmaceuticals obtains license to ticagrelor reversal agent

Nov. 29, 2017

VE-2851, a promising novel thrombin inhibitor with low bleeding risk

Nov. 28, 2017

FDA grants priority review to Dova's NDA for avatrombopag

Nov. 28, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...